Kevin Choy, MD
Ophthalmology · Los Angeles, CANPI 1174731285
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,547 and has fallen 64.6% since, to $547 in 2025.
Across 135 payments — averaging $29.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$745
- Aerie Pharmaceuticals, Inc.$633
- AbbVie$583
- Bausch & Lomb, A Division Of Bausch Health US, LLC$500
- Glaukos Corporation$361
- Shockwave Medical, Inc$270
- plus $942 from 13 others
What the payments were for
- Food & beverage$4,033100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 21 | $745 |
| Aerie Pharmaceuticals, Inc. | 29 | $633 |
| AbbVie(2 entities) | 32 | $583 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $500 |
| Glaukos Corporation | 4 | $361 |
| Shockwave Medical, Inc | 4 | $270 |
| Mallinckrodt Hospital Products Inc. | 6 | $145 |
| Eyepoint US, Inc. | 1 | $133 |
| Bausch & Lomb Americas Inc. | 5 | $104 |
| Stryker | 4 | $92 |
| Shire North American Group Inc | 4 | $92 |
| Amgen | 4 | $87 |
| Novartis | 3 | $67 |
| Biotissue Holdings Inc. | 2 | $51 |
| Eyevance Pharmaceuticals LLC | 3 | $50 |
| Thea Pharma Inc. | 2 | $42 |
| Sun Pharmaceutical Industries Inc. | 1 | $36 |
| Abiomed | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOTEMAX SM$239
- Rhopressa$231
- Rocklatan$231
- iStent$141
- iStent inject W$141
- KXL System$141
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$134
- DEXYCU$133
- iStent Trabecular Micro-Bypass Stent System$125
- iStent inject Trabecular Micro-Bypass Stent System$125
- Centurion$123
- AcrySof$122
- Unity$121
- ALREX$101
- BEPREVE$101
How this compares
$4,033 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 217 | $152,625 |
| LumiganBimatoprost | 188 | $77,890 |
| Cyclosporine | 184 | $73,603 |
| RhopressaNetarsudil Mesylate | 143 | $56,195 |
| Alphagan PBrimonidine Tartrate | 105 | $36,685 |
| ProlensaBromfenac Sodium | 61 | $21,173 |
| Prednisolone Acetate | 296 | $16,675 |
| Brimonidine Tartrate | 186 | $15,572 |
| RocklatanNetarsudil Mesylat/Latanoprost | 43 | $14,374 |
| XiidraLifitegrast | 16 | $13,594 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 57 | $12,561 |
| Azelastine Hcl | 836 | $11,604 |
| Travoprost | 82 | $10,807 |
| Latanoprost | 1,577 | $10,720 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 400 | $7,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $583 | $274,605538 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $633 | $70,569186 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $500 | $21,17361 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $104 | $20,52942 claims |
| AlconSimbrinza, Azopt | $745 | $18,14972 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Los Angeles
- Andrew MoshfeghiLos Angeles$895K
- Barry SeibelLos Angeles$835K
- Nicole FramLos Angeles$551K
- Neda ShamieLos Angeles$547K
- David BoyerLos Angeles$406K
- David HamiltonLos Angeles$359K
- Arjan HuraLos Angeles$306K
- Firas RahhalLos Angeles$264K
- Kouros NourimahdaviLos Angeles$258K
- Daniel RootmanLos Angeles$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.